159 related articles for article (PubMed ID: 20091763)
1. Dangerous omissions: the consequences of ignoring decision uncertainty.
Griffin SC; Claxton KP; Palmer SJ; Sculpher MJ
Health Econ; 2011 Feb; 20(2):212-24. PubMed ID: 20091763
[TBL] [Abstract][Full Text] [Related]
2. A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; Soares M; Spackman E; Rothery C
Value Health; 2016; 19(6):885-891. PubMed ID: 27712718
[TBL] [Abstract][Full Text] [Related]
3. Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments Required.
McKenna C; Soares M; Claxton K; Bojke L; Griffin S; Palmer S; Spackman E
Value Health; 2015 Sep; 18(6):865-75. PubMed ID: 26409615
[TBL] [Abstract][Full Text] [Related]
4. Characterising Uncertainty in the Assessment of Medical Devices and Determining Future Research Needs.
Rothery C; Claxton K; Palmer S; Epstein D; Tarricone R; Sculpher M
Health Econ; 2017 Feb; 26 Suppl 1():109-123. PubMed ID: 28139090
[TBL] [Abstract][Full Text] [Related]
5. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
Eckermann S; Willan AR
Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
[TBL] [Abstract][Full Text] [Related]
6. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
7. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
[TBL] [Abstract][Full Text] [Related]
8. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.
Hagiwara Y; Shiroiwa T
Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648
[TBL] [Abstract][Full Text] [Related]
9. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
[TBL] [Abstract][Full Text] [Related]
10. Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.
Guzauskas GF; Basu A; Carlson JJ; Veenstra DL
Value Health; 2019 Sep; 22(9):988-994. PubMed ID: 31511188
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Decision Makers' Constraints on the Outcome of Value of Information Analysis.
Koffijberg H; Knies S; Janssen MP
Value Health; 2018 Feb; 21(2):203-209. PubMed ID: 29477402
[TBL] [Abstract][Full Text] [Related]
12. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
13. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
14. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
15. Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT.
Clarkson JE; Pitts NB; Goulao B; Boyers D; Ramsay CR; Floate R; Braid HJ; Fee PA; Ord FS; Worthington HV; van der Pol M; Young L; Freeman R; Gouick J; Humphris GM; Mitchell FE; McDonald AM; Norrie JD; Sim K; Douglas G; Ricketts D
Health Technol Assess; 2020 Nov; 24(60):1-138. PubMed ID: 33215986
[TBL] [Abstract][Full Text] [Related]
16. Health technology assessment and policy from the economic perspective.
Rutten F
Int J Technol Assess Health Care; 2004; 20(1):67-70. PubMed ID: 15176179
[TBL] [Abstract][Full Text] [Related]
17. Severity-Adjusted Probability of Being Cost Effective.
Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
[TBL] [Abstract][Full Text] [Related]
18. Value of research and value of development in early assessments of new medical technologies.
Retèl VP; Grutters JP; van Harten WH; Joore MA
Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
[TBL] [Abstract][Full Text] [Related]
19. Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System.
Edney LC; Haji Ali Afzali H; Cheng TC; Karnon J
Pharmacoeconomics; 2018 Feb; 36(2):239-252. PubMed ID: 29273843
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
